NCT05739565 Impact of a Physical Activity Intervention With Motivational Support From Peers for Prostate Cancer Patients
| NCT ID | NCT05739565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 850 participants |
| Start Date | 2023-04-25 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 850 participants in total. It began in 2023-04-25 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Despite the recognized benefits of physical activity in tertiary prevention, 60-70% of prostate cancer patients are insufficiently active. Yet 150 minutes of brisk walking per week (new WHO recommendations) is associated with a 29% reduction in cancer mortality and a 57% reduction in recurrence. Increasing patients' adherence to regular physical activity appears to be a new challenge for personalized cancer care. Personalized physical activity programmes (1) at home, (2) supported by health professionals, or (3) by peers have shown the effectiveness of regular physical activity. However, these interventions last less than 6 months and do not allow for long-term sustainability of physical activity. This study proposes to combine 3 interventions, which aim to initiate and maintain regular physical activity in prostate cancer patients: * 1-The realization of a personalized and realistic physical activity project via physical activity support devices (sport health centers) * 2-Coaching by a peer (a patient with the same disease who has reached the WHO recommendations for physical activity), who will provide motivational follow-up * 3-Support by health professionals (attending physician) through the prescription of physical activity. The feasibility of ACTI-PAIR program has been demonstrated, the investigators now wish to evaluate it effectiveness.
Eligibility Criteria
Inclusion Criteria: Patients: * Age ≥ 18 years * Diagnosed with prostate cancer for at least 1 year * PA practice \< 150 minutes per week (considered inactive according to WHO) * Affiliated or entitled to a social security scheme * Having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study Exclusion Criteria: For patients: * Undergoing treatment (except hormone therapy) * Significant comorbidities contraindicating the practice of physical activity: associated cardiac pathologies, respiratory pathologies, disabling joint pathologies * Deprived of liberty or under guardianship
Contact & Investigator
David HUPIN, MD PhD
PRINCIPAL INVESTIGATOR
CHU de Saint-Etienne
Frequently Asked Questions
Who can join the NCT05739565 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05739565 currently recruiting?
Yes, NCT05739565 is actively recruiting participants. Contact the research team at David.Hupin@chu-st-etienne.fr for enrollment information.
Where is the NCT05739565 trial being conducted?
This trial is being conducted at Chambéry, France, Chambéry, France, Clermont-Ferrand, France, Clermont-Ferrand, France and 11 additional locations.
Who is sponsoring the NCT05739565 clinical trial?
NCT05739565 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is David HUPIN, MD PhD at CHU de Saint-Etienne. The trial plans to enroll 850 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.